LBA34 Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials

David M. O’Malley, Ana Oaknin, Bradley J. Monk, Alexandra Léary, Frédèric Selle, Jérôme Alexandre, Leslie M. Randall, Carlos A. Rojas, Maryna Neffa, Anna Kryzhanivska, Laurence Gladieff, Dominique Berton, Tarek Meniawy, Iwona Ługowska, Igor Bondarenko, Kathleen N. Moore, W.I. Ortuzar Feliu, Marek Ancukiewicz, Irina M. Shapiro, Isabelle Laure Ray-Coquard